Neighborhood archetypes and breast cancer survival in California.

Breast cancer Cancer survival Geographic disparities Latent class analysis Neighborhood archetypes Neighborhood socioeconomic status Racial/ethnic disparities

Journal

Annals of epidemiology
ISSN: 1873-2585
Titre abrégé: Ann Epidemiol
Pays: United States
ID NLM: 9100013

Informations de publication

Date de publication:
05 2021
Historique:
received: 01 09 2020
revised: 24 01 2021
accepted: 26 01 2021
pubmed: 13 2 2021
medline: 11 5 2021
entrez: 12 2 2021
Statut: ppublish

Résumé

Previous studies on neighborhoods and breast cancer survival examined neighborhood variables as unidimensional measures (e.g. walkability or deprivation) individually and thus cannot inform how the multitude of highly correlated neighborhood domains interact to impact breast cancer survival. Neighborhood archetypes were developed that consider interactions among a broad range of neighborhood social and built environment attributes and examine their associations with breast cancer survival. Archetypes were measured using latent class analysis (LCA) fit to California census tract-level data. Thirty-nine social and built environment attributes relevant to eight neighborhood domains (socioeconomic status (SES), urbanicity, demographics, housing, land use, commuting and traffic, residential mobility, and food environment) were included.  The archetypes were linked to cancer registry data on breast cancer cases (diagnosed 1996-2005 with follow-up through Dec 31, 2017) to evaluate their associations with overall and breast cancer-specific survival using Cox proportional hazards models. Analyses were stratified by race/ethnicity. California neighborhoods were best described by nine archetypal patterns that were differentially associated with overall and breast cancer-specific survival. The lowest risk of overall death was observed in the upper middle class suburb (reference) and high status neighborhoods, while the highest was observed among inner city residents with a 39% greater risk of death (95% CI = 1.35 to 1.44). Results were similar for breast cancer-specific survival. Stratified analyses indicated that differences in survival by neighborhood archetypes varied according to individuals' race/ethnicity. By describing neighborhood archetypes that differentiate survival following breast cancer diagnosis, the study provides direction for policy and clinical practice addressing contextually-rooted social determinants of health including SES, unhealthy food environments, and greenspace.

Identifiants

pubmed: 33577928
pii: S1047-2797(21)00013-2
doi: 10.1016/j.annepidem.2021.01.004
pmc: PMC8133764
mid: NIHMS1672357
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

22-29

Subventions

Organisme : NCI NIH HHS
ID : HHSN261201800032C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800009C
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : NU58DP006344
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800015I
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800032I
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800015C
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA174469
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800009I
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Références

Am J Public Health. 2019 Jan;109(S1):S16-S20
pubmed: 30699025
Int J Epidemiol. 2001 Aug;30(4):668-77
pubmed: 11511581
Cancer Causes Control. 2014 Oct;25(10):1295-308
pubmed: 25088804
Soc Sci Med. 2012 Apr;74(8):1204-12
pubmed: 22365939
Am Psychol. 1999 Oct;54(10):805-16
pubmed: 10540593
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):516-524
pubmed: 28325737
PLoS One. 2012;7(8):e44325
pubmed: 22957007
Ann Epidemiol. 2018 May;28(5):316-321.e2
pubmed: 29678311
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):793-811
pubmed: 24618999
Cancer Causes Control. 2011 Apr;22(4):631-47
pubmed: 21318584
Int J Health Serv. 1999;29(2):295-352
pubmed: 10379455
Am J Prev Med. 2018 Jan;54(1):87-95
pubmed: 29254556
J Chronic Dis. 1970 Aug;23(2):105-15
pubmed: 5455352
Breast Cancer Res Treat. 2012 Apr;132(2):701-10
pubmed: 22160639
Health Place. 2010 Sep;16(5):1038-52
pubmed: 20630792
J Urban Health. 2011 Dec;88(6):1117-29
pubmed: 21847712
Int J Behav Nutr Phys Act. 2013 Mar 14;10:34
pubmed: 23497187
J Community Health. 2015 Dec;40(6):1287-99
pubmed: 26072260
Cancer. 2011 Apr 1;117(7):1542-51
pubmed: 21425155
Prof Geogr. 2008 Feb;60(1):54-69
pubmed: 18458760
Am J Prev Med. 2015 Dec;49(6):878-87
pubmed: 26232902
Cancer. 2008 Aug 1;113(3):582-91
pubmed: 18613122
Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):821-7
pubmed: 19240237
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Am J Public Health. 2019 Jan;109(S1):S21-S24
pubmed: 30699031
Breast Cancer Res Treat. 2014 Oct;147(3):661-70
pubmed: 25234843
Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):121-31
pubmed: 19124489
Cancer. 2008 Feb 15;112(4):909-18
pubmed: 18189295
J Community Health. 2010 Aug;35(4):398-408
pubmed: 20358266
Am J Public Health. 2002 Apr;92(4):588-97
pubmed: 11919058
Am J Epidemiol. 2002 Sep 1;156(5):471-82
pubmed: 12196317
J Clin Oncol. 2018 Jan 1;36(1):25-33
pubmed: 29035642
Cancer Epidemiol. 2018 Apr;53:1-11
pubmed: 29328959
Health Serv Res. 2012 Jun;47(3 Pt 2):1255-77
pubmed: 22568674
Am J Public Health. 1986 Dec;76(12):1400-3
pubmed: 3777285
Am J Prev Med. 2009 Nov;37(5):455-63
pubmed: 19840702
J Public Health Manag Pract. 2010 Sep-Oct;16(5):411-9
pubmed: 20689390
Cancer Causes Control. 2012 Sep;23(9):1519-27
pubmed: 22825071
JAMA. 2005 Dec 14;294(22):2879-88
pubmed: 16352796
Cancer. 2015 Jul 15;121(14):2314-30
pubmed: 25847484
Prev Chronic Dis. 2014 Feb 13;11:E21
pubmed: 24524425
Cancer Causes Control. 2016 Mar;27(3):445-52
pubmed: 26797452
Annu Rev Public Health. 2014;35:29-45
pubmed: 24188053
Ann N Y Acad Sci. 2010 Feb;1186:125-45
pubmed: 20201871
BMC Cancer. 2010 Nov 04;10:603
pubmed: 21050464
Health Place. 2015 Nov;36:162-72
pubmed: 26606455
Health Place. 2014 May;27:134-41
pubmed: 24607872
Cancer. 2015 Jun 1;121(11):1845-55
pubmed: 25678448
BMC Public Health. 2013 Dec 01;13:1103
pubmed: 24289151
Health Place. 2011 Jan;17(1):289-99
pubmed: 21168356
Prev Sci. 2013 Apr;14(2):157-68
pubmed: 21318625
J Pers. 2009 Dec;77(6):1707-46
pubmed: 19796063
J Natl Med Assoc. 2006 Mar;98(3):386-96
pubmed: 16573303
Cancer. 2010 Jul 15;116(14):3493-504
pubmed: 20549763
Am J Public Health. 2016 Feb;106(2):256-63
pubmed: 26691119
Am J Public Health. 2008 Sep;98(9):1608-15
pubmed: 18633099
BMC Cancer. 2009 Oct 14;9:364
pubmed: 19828016
Breast Cancer Res Treat. 2014 Apr;144(3):625-34
pubmed: 24658879
Health Aff (Millwood). 2005 Mar-Apr;24(2):325-34
pubmed: 15757915
Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1282-90
pubmed: 26063477
Cancer. 2018 May 1;124(9):1877-1903
pubmed: 29411868
Health Place. 2015 May;33:9-18
pubmed: 25723792
Am J Public Health. 2010 May;100(5):861-9
pubmed: 20299648
Health Place. 2012 Mar;18(2):191-8
pubmed: 21975286

Auteurs

Salma Shariff-Marco (S)

Department of Epidemiology & Biostatistics, University of California, San Francisco (UCSF), San Francisco, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Greater Bay Area Cancer Registry, San Francisco, CA. Electronic address: salma.shariff-marco@ucsf.edu.

Mindy C DeRouen (MC)

Department of Epidemiology & Biostatistics, University of California, San Francisco (UCSF), San Francisco, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.

Juan Yang (J)

Department of Epidemiology & Biostatistics, University of California, San Francisco (UCSF), San Francisco, CA; Greater Bay Area Cancer Registry, San Francisco, CA.

Jennifer Jain (J)

Department of Epidemiology & Biostatistics, University of California, San Francisco (UCSF), San Francisco, CA; Greater Bay Area Cancer Registry, San Francisco, CA.

David O Nelson (DO)

Cancer Prevention Institute of California, Fremont, CA.

Margaret M Weden (MM)

RAND Corporation, Santa Monica, CA.

Scarlett L Gomez (SL)

Department of Epidemiology & Biostatistics, University of California, San Francisco (UCSF), San Francisco, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Greater Bay Area Cancer Registry, San Francisco, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH